Ocular inserts for topical delivery

Richardson, 1975, Ocular microtherapy: membrane-controlled drug delivery, Arch. Ophthalmol., 93, 74, 10.1001/archopht.1975.01010020078014 Shell, 1980, New ophthalmic drug delivery systems, 71 Chien, 1982, Ocular controlled drug administration, 13 Norio, 1983, Ocular pharmacology of drug release devices, Vol. 2, 90 Shell, 1984, Ophthalmic drug delivery systems, Surv. Ophthalmol., 29, 117, 10.1016/0039-6257(84)90168-1 Buri, 1985, Voie oculaire, 411 Lee, 1986, Review: Topical ocular drug delivery: recent developments and future challenges, J. Ocul. Pharmacol., 2, 67, 10.1089/jop.1986.2.67 Salminen, 1987, Pilocarpine inserts, experimental and clinical experiences, Vol. 11, 161 Lee, 1990, Review: New directions in the optimization of ocular drug delivery, J. Ocul. Pharmacol., 6, 157, 10.1089/jop.1990.6.157 Saettone, 1993, Solid polymeric inserts/disks as ocular drug delivery systems, 61 Bawa, 1993, Ocular inserts, 223 Hill, 1993, Corneal collagen shields for ocular delivery, 261 Richardson, 1993, A new ophthalmic delivery system, 355 Lee, 1993, Precorneal, corneal and postcorneal factors, 59 Heller, 1987, Controlled drug release from monolithic systems, Vol. 11, 179 Korsmeyer, 1983, Macromolecular and modeling aspects of swelling-controlled systems, 77 Heller, 1980, Controlled release of biologically active compounds from bioerodible polymers, Biomaterials, 1, 51, 10.1016/0142-9612(80)90060-5 Brinchmann-Hansen, 1993, Pilocarpine drops do not reduce intraocular pressure sufficiently in pseudoexfoliation glaucoma, Eye, 7, 511, 10.1038/eye.1993.111 Urtti, 1994, Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans, Pharm. Res., 11, 1278, 10.1023/A:1018938310628 Keller, 1976, Intermittent vs. continuous steroid administration. Efficacy in experimental conjunctivitis, Arch. Ophthalmol., 94, 644, 10.1001/archopht.1976.03910030316013 Leibowitz, 1979, Optimal frequency of topical prednisolone administration, Arch. Ophthalmol., 97, 2154, 10.1001/archopht.1979.01020020472014 Norell, 1980, Self-medication with pilocarpine among outpatients in a glaucoma clinic, Br. J. Ophthalmol., 64, 137, 10.1136/bjo.64.2.137 Kass, 1982, Patient administration of eyedrops: observation, Ann. Ophthalmol., 14, 889 Khromow, 1976 Maichuk, 1985, Medicated Eye Films, 1 Maichuk, 1967, Polymeric ophthalmic inserts with antibiotics, 403 Maichuk, 1975, Ophthalmic drug inserts, Invest. Ophthalmol., 14, 87 Maichuk, 1975, Soluble ophthalmic drug inserts, Lancet, i, 173, 10.1016/S0140-6736(75)91481-6 Maichuk, 1976, Polymeric drug delivery systems in ophthalmology, 1 Maichuk, 1981, Soluble ophthalmic drug inserts with pilocarpine, experimental and clinical study, Glaucoma, 3, 329 Urquhart, 1980, Development of the Ocusert pilocarpine ocular therapeutic systems: A case history in ophthalmic product development, 105 Lerman, 1970, Simulated sustained-release pilocarpine therapy, Ann. Ophthalmol., 2, 235 Lerman, 1971, Simulated sustained release pilocarpine therapy and aqueous humour dynamics, Can. J. Ophthalmol., 6, 14 Shell, 1974, Diffusional systems for controlled release of drugs to the eye, Ann. Ophthalmol., 6, 1037 Leydhecker, 1975, Ocusert, Summary of a round table discussion, Klin. Monatsbl. Augenheilkd., 167, 917 Fyodorov, 1985, Comprehensive conservative treatment of dystrophia endothelialis et epithelialis corneae, using a therapeutic collagen coating, Vestn. Oftalmol., 101, 33 Shofner, 1989, New horizons in ocular drug delivery, Ophthalmol. Clin. North Am., 2, 15 Mondino, 1991, Collagen shields, Am. J. Ophthalmol., 112, 587, 10.1016/S0002-9394(14)76863-1 Bloomfield, 1977, Soluble artificial tear inserts, Arch. Ophthalmol., 95, 247, 10.1001/archopht.1977.04450020048009 Bloomfield, 1978, Soluble gentamycin ophthalmic inserts as a drug delivery system, Arch. Ophthalmol., 96, 885, 10.1001/archopht.1978.03910050487020 Reidy, 1990, The collagen shield. A new vehicle for delivery of cyclosporin A to the eye, Cornea, 9, 196, 10.1097/00003226-199007000-00003 Jacob-La Barre, 1992, Two collagen-based drug delivery systems: nanoparticles in collagen matrix vs. hydrophobically modified collagen matrix, 111 Kortüm, 1994, Uptake and release of intact liposomes by collagen corneal shields, Invest. Ophthalmol. Vis. Sci., 35, 2220 Kaufman, 1988, 14, 487 Poland, 1988, Clinical uses of collagen shields, J. Cataract Refract. Surg., 14, 489, 10.1016/S0886-3350(88)80003-8 Friedberg, 1991, Device drug delivery to the eye. Collagen shields, iontophoresis and pumps, Ophthalmology, 98, 725, 10.1016/S0161-6420(91)32227-9 Milani, 1993, Collagen shields impregnated with gentaminic-dexamethasone as a potential drug delivery device, Am. J. Ophthalmol., 116, 622, 10.1016/S0002-9394(14)73206-4 Wentworth, 1993, Collagen shields exacerbate ulceration of alkali-burned rabbit corneas, Arch. Ophthalmol., 111, 389, 10.1001/archopht.1993.01090030109050 Kaufman, 1994, Collagen-based drug delivery and artificial tears, J. Ocul. Pharmacol., 10, 17, 10.1089/jop.1994.10.17 Darougar, 1992 Katz, 1977, A soluble sustained-release ophthalmic delivery unit, Am. J. Ophthalmol., 83, 728, 10.1016/0002-9394(77)90141-6 Lamberts, 1978, A clinical study of slow-releasing artificial tears, Ophthalmology, 85, 794, 10.1016/S0161-6420(78)35610-4 Urtti, 1990, Controlled drug delivery devices for experimental ocular studies with timolol. 1. In vitro release studies, Int. J. Pharm., 61, 235, 10.1016/0378-5173(90)90214-O Weiner, 1993, Long term retention of a sustained drug release ocular insert (Ocufit SR) in the fornix of human volunteers, Invest. Ophthalmol. Vis. Sci., 34, 1489 Weiner, 1993, A sustained release ocular insert (Ocufit SR) with long term retention in the fornix of humans, 20, 384 Urtti, 1988, Application site dependent ocular absorption of timolol, J. Ocular Pharmacol., 4, 335, 10.1089/jop.1988.4.335 Wong, 1994, Upper lid administration of ophthalmic medications: a fluorophotometric study, Invest. Ophthalmol. Vis. Sci., 35, 2221 Bawa, 1988, New extended release ocular drug delivery system. Design, characterization and performance testing of minidisc inserts, 15, 106a Bawa, 1989, Recent studies on the continuing characterization of minidisc inserts for ocular therapy, 16, 213 Lloyd, R. (1985) U.K. Patent 2097680 (Smith & Nephew Research, Ltd). Kelly, 1989, Relative bioavailability of pilocarpine from a novel ophthalmic delivery system and conventional eyedrop formulations, Br. J. Ophthalmol., 7, 360, 10.1136/bjo.73.5.360 Fitzgerald, 1992, Scintigraphic assessment of the precorneal residence of a new ophthalmic delivery system (NODS) in man, Int. J. Pharm., 83, 177, 10.1016/0378-5173(82)90021-7 Greaves, 1992, Scintigraphic studies on the corneal residence of a new ophthalmic delivery system (NODS): rate of clearance of a soluble marker in relation to duration of pharmacological action of pilocarpine, Br. J. Clin. Pharmacol., 33, 603, 10.1111/j.1365-2125.1992.tb04088.x Lunn, J.N.T., Chauvin Pharmaceuticals, Ltd. (1995) Personal communication. Bernatchez, 1994, Biocompatibilily of a new semisolid bioerodible poly(ortho ester) intended for the ocular delivery of 5-fluorouracil, J. Biomed. Mater. Res., 28, 1037, 10.1002/jbm.820280908 Rubsamen, 1994, Prevention of experimental proliferative vitroretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil, Arch. Ophthalmol., 112, 407, 10.1001/archopht.1994.01090150137036